The Department of Health (DH) today (March 8) endorsed a licensed drug wholesaler, Mediline (Hong Kong) Company Limited (Mediline), to recall all batches of Dertec Cream (registration number: HK-62290) from the market due to a quality issue.
During the DH's market surveillance, samples of the above product were collected for analysis. Testing results from the Government Laboratory revealed that the content of one of the active ingredients, namely clioquinol, was found to be less than the labelled claim, which might affect the efficacy of the product.
Mediline voluntarily recalled the product from the market and was instructed to report the root cause to the DH upon investigation by the manufacturer in Thailand.
Dertec Cream, containing betamethasone, tolnaftate, gentamycin and clioquinol, is a prescription-only medicine used to treat skin inflammation and infections. According to the wholesaler, the product has been supplied to private doctors and local pharmacies.
Mediline has set up a hotline (3568 6520) to answer related enquiries.
"So far, the DH has not received any adverse reaction reports in connection with the above product. The DH's investigation is continuing and will closely monitor the recall," a spokesman for the DH said.
"Members of the public should consult healthcare professionals if in doubt or feeling unwell after using the product," the spokesman added.
Reprinted from HKSAR Government:
http://www.info.gov.hk/gia/general/201803/08/P2018030800642.htm